Gil taucht ab
Heute ist Gilead Sciences auf Tauchstation. Anlass sind die neuen Quartalszahlen. Unsere Geduld könnte sich auszahlen. So sind wir den stark steigenden Kursen im Sommer nicht hinterhergelaufen, sondern haben in aller Ruhe auf den zu erwartenden Rückschlag gewartet. What goes up, must come down. Wir bleiben aber noch in Lauerstellung.
Dieser Analyst bleibt zumindest zuversichtlich:
Gilead beats on both top and bottom-line of Wall Street’s estimates.
Gilead raised its lower end of guidance for revenue in 2017.
Acquisition of Kite Pharma will drive value for Gilead in the long-term.
Legacy products such as the HIV drugs and Hepatitis B treatments picked up the slack for the lagging Hep C sales during the quarter.
Kite Pharma’s pipeline not only added Yescarta into the mix; it added two CAR-T therapies, and one T-cell receptor product.
After the closing bell on Thursday, Gilead Sciences (GILD) reported earnings for the third-quarter, which beat Wall Street’s estimates. It was a pretty solid quarter, as it had beat on both the top-line and bottom-line of estimates. The only issue that remains is that Hepatitis C sales continue to lag. Even then, the company still managed to beat on earnings for the quarter. In addition, it was able to raise its lower end guidance of revenue for the rest of 2017. I feel that the company is still a great buy after its reported numbers. In terms of Hepatitis C sales, they have been declining for quite some time now. That’s the point, in that it has been known for a long time that sales of Gilead’s Hep C franchise has been shrinking. Despite the decline of Hep C sales, the company has been doing well with its other programs. I feel that Gilead will be fine in the coming years, and the recent buy of Kite Pharma (KITE)should ultimately help it branch out to other cancer indications.
Adjusted profit for the third-quarter came in at $2.27 a share, which beat analysts‘ forecast for $2.13 a share. Gilead reported that it had earned $6.51 billion revenue for the third-quarter which also came above estimates for $6.33 billion. Taking a look at the numbers, I have to say that Gilead had a great quarter. Especially, when you consider the fact that Hepatitis C sales have been shrinking. In my opinion, it’s pretty amazing for a company to still beat on Wall Street’s estimates despite the huge overhang on declining Hep C sales. Even then, Hepatitis C sales are not dropping by a monumental amount. Gilead guided that its Hep C sales for the full year would drop down to $9 billion from a prior high end estimate of $9.5 billion. That is a drop in Hep C guidance, but not by much. It doesn’t mean that the company will collapse because of a slightly lower guide on Hep C sales. Also when thinking about guidance for 2018, analysts are probably already aware of declining Hep C sales. That means that estimates for Hep C sales from Wall Street, should come down in 2018. If that happens, then Gilead will have an easy time beating analysts‘ estimates for each quarter in 2018.